Topical composition

The combination of vitamin D3, glucocorticoids, and specific nonionic surfactants in a topical composition stabilizes vitamin D3 even at high water content, addressing the stability issue and ensuring effective psoriasis treatment.

WO2024237181A1PCT designated stage expired Publication Date: 2024-11-21API CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/017355
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-05-10
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Vitamin D3 stability decreases when dissolved in water, posing a challenge for topical compositions containing vitamin D3 and glucocorticoids, especially with increasing water content.

Method used

A composition combining vitamin D3, glucocorticoids, polyoxyalkylene hydrogenated castor oil as nonionic surfactant A, and other nonionic surfactants like polyoxyalkylene alkyl ether or polyoxyalkylene glycol, with an HLB value of 6 or more, along with ester oil, to enhance stability even at high water content.

Benefits of technology

The composition maintains the stability of vitamin D3 and glucocorticoids, as evidenced by residual rate analysis at 60°C, demonstrating improved stability without adverse effects on glucocorticoid stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024017355_21112024_PF_FP_ABST
    Figure JP2024017355_21112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided is a feature of further improving the stability of vitamin D3 in a topical composition containing vitamin D3 and a glucocorticoid, even when the water content in the topical composition is increased. The topical composition contains vitamin D3, a glucocorticoid, a nonionic surfactant A that is a polyoxyalkylene hydrogenated castor oil, and a nonionic surfactant B that is a nonionic surfactant other than the polyoxyalkylene hydrogenated castor oil.
Need to check novelty before this filing date? Find Prior Art

Description

External composition

[0001] The present invention relates to a topical composition and the like.

[0002] Psoriasis is a skin disease characterized by major symptoms such as skin keratinization, scaling, thickened skin, and red rash, affecting hundreds of thousands of people in Japan. Vitamin D3 is known to be used as a topical medication for psoriasis. It is also known that vitamin D3 and glucocorticoids are used in combination as topical medications for psoriasis (Patent Document 1).

[0003] Special table 2021-518409 publication

[0004] Although vitamin D3 has excellent medicinal properties, its stability decreases when dissolved in water, and the greater the water content, the greater the stability problem.

[0005] Therefore, an objective of the present invention is to provide a technology for further improving the stability of vitamin D3 in an external composition containing vitamin D3 and a glucocorticoid, even when the water content in the external composition is increased.

[0006] Item 1. A composition for external use containing vitamin D3, a glucocorticoid, a nonionic surfactant A which is a polyoxyalkylene hydrogenated castor oil, and a nonionic surfactant B which is a nonionic surfactant other than a polyoxyalkylene hydrogenated castor oil.

[0007] Item 2. The topical composition for topical use according to Item 1, wherein the nonionic surfactant B is at least one selected from the group consisting of polyoxyalkylene alkyl ethers, polyoxyalkylene glycols, polyoxyalkylene fatty acid esters, polyoxyalkylene sorbite fatty acid esters, and polyglycerin fatty acid esters.

[0008] Item 3. The composition for external use according to Item 1 or 2, wherein the nonionic surfactant B has an HLB value of 6 or more.

[0009] Item 4. The topical composition according to any one of Items 1 to 3, wherein the total content of the nonionic surfactant A and the nonionic surfactant B in the topical composition is 0.5% by mass or more and 10% by mass or less.

[0010] Item 5. The composition for topical use according to any one of Items 1 to 4, wherein the content of the nonionic surfactant A in the total of the nonionic surfactant A and the nonionic surfactant B is 10% by mass or more and 99.9% by mass or less.

[0011] Item 6. The topical composition for external use according to any one of Items 1 to 5, which contains an ester oil.

[0012] Item 7. The topical composition for external use according to Item 6, wherein the ester oil contains at least glycerin triisooctanoate.

[0013] Item 8. The topical composition for topical use according to any one of Items 1 to 7, wherein the nonionic surfactant B is at least one selected from the group consisting of polyoxyalkylene alkyl ethers, polyoxyalkylene glycols, polyoxyalkylene fatty acid esters, polyoxyalkylene sorbite fatty acid esters, and polyglycerin fatty acid esters, the HLB value of the nonionic surfactant B is 6 or higher, the total content of the nonionic surfactant A and the nonionic surfactant B in the topical composition is 1% by mass or more and 10% by mass or less, the content of the nonionic surfactant A in the total of the nonionic surfactant A and the nonionic surfactant B is 10% by mass or more and 99.9% by mass or less, and the topical composition contains an ester oil.

[0014] Item 9. The composition for external use according to any one of Items 1 to 8, wherein the vitamin D3 is at least one selected from the group consisting of calcipotriol, maxacalcitol, alfacalcidol, falecalcitriol, tacalcitol, and calcitriol.

[0015] Item 10. The composition for external use according to any one of Items 1 to 9, wherein the vitamin D3 is calcipotriol, the glucocorticoid is betamethasone dipropionate, the polyoxyalkylene hydrogenated castor oil is polyoxyethylene hydrogenated castor oil, and the nonionic surfactant B is at least one selected from the group consisting of polyoxyalkylene alkyl ethers, polyoxyalkylene glycols, polyoxyalkylene fatty acid esters, polyoxyalkylene sorbite fatty acid esters, and polyglycerin fatty acid esters.

[0016] Item 11. The composition for topical use according to any one of Items 1 to 10, wherein the nonionic surfactant B is one or more selected from polyoxyethylene polyoxypropylene cetyl ether, polyoxyethylene lauryl ether, polyoxyethylene polyoxypropylene glycol, polyethylene glycol monostearate, polyoxyethylene sorbitol tetraoleate, and polyglyceryl monolaurate.

[0017] Item 12. The topical composition for external use according to any one of Items 1 to 11, wherein the polyoxyalkylene hydrogenated castor oil has an average number of alkylene oxide moles added of less than 60.

[0018] Item 13. The topical composition according to Item 12, wherein the alkylene oxide group is ethylene oxide.

[0019] Item 14. The topical composition for external use according to any one of Items 1 to 13, wherein the polyoxyethylene hydrogenated castor oil has an average number of moles of ethylene oxide added of less than 60.

[0020] Item 15. The composition for external use according to any one of Items 1 to 14, further comprising water.

[0021] Item 16. The composition for external use according to Item 15, wherein the content of water in the composition for external use is 40% by mass or more.

[0022] Item 17. The composition for external use according to Item 15, wherein the content of water in the composition for external use is 75% by mass or more.

[0023] Item 18. The composition for external use according to any one of Items 1 to 17, wherein the content of vitamin D3 in the composition for external use is 0.0001% by mass or more and 0.2% by mass or less.

[0024] Item 19. The composition for external use according to any one of Items 1 to 18, wherein the content of the glucocorticoid in the composition for external use is 0.001% by mass or more and 2% by mass or less.

[0025] Item 20. The topical composition according to any one of Items 1 to 19, further comprising an antioxidant.

[0026] Item 21. The composition for external use according to any one of Items 1 to 20, which is in the form of a gel, liquid, aerosol, mist, or foam.

[0027] Item 22. The composition for external use according to any one of Items 1 to 21, which is used for preventing or ameliorating psoriasis.

[0028] In view of the above problems, the present inventors have conducted extensive research and found that the above problems can be solved by a topical composition containing vitamin D3, a glucocorticoid, a nonionic surfactant A which is a polyoxyalkylene hydrogenated castor oil, and a nonionic surfactant B which is a nonionic surfactant other than polyoxyalkylene hydrogenated castor oil. Based on this finding, the present inventors have conducted further research and have completed the present invention. Specifically, the present invention encompasses the following aspects:

[0029] According to the present invention, it is possible to provide a composition for external use that contains vitamin D3 and a glucocorticoid and has improved stability of vitamin D3 even when the water content of the composition is high.

[0030] The vertical axis shows the residual rates of vitamin D3 (upper row) and glucocorticoids (lower row) when liquid compositions (Example 1, Comparative Example 1, Comparative Example 2) were allowed to stand at 60°C. The horizontal axis shows the number of weeks elapsed since the start of standing at 60°C. The vertical axis shows the residual rates of vitamin D3 (upper row) and glucocorticoids (lower row) when liquid compositions (Example 2, Comparative Example 1, Comparative Example 3) were allowed to stand at 60°C. The horizontal axis shows the number of weeks elapsed since the start of standing at 60°C. The vertical axis shows the residual rates of vitamin D3 (upper row) and glucocorticoids (lower row) when liquid compositions (Example 3, Comparative Example 1, Comparative Example 4) were allowed to stand at 60°C. The horizontal axis shows the number of weeks elapsed since the start of standing at 60°C. The vertical axis shows the residual rates of vitamin D3 (upper row) and glucocorticoids (lower row) when liquid compositions (Example 4, Comparative Example 1, Comparative Example 5) were allowed to stand at 60°C. The horizontal axis shows the number of weeks elapsed since the start of standing at 60°C. The vertical axis shows the residual rates of vitamin D3 (upper row) and glucocorticoids (lower row) when liquid compositions (Example 5, Comparative Example 1, Comparative Example 6) were allowed to stand at 60°C. The horizontal axis shows the number of weeks elapsed since the start of standing at 60°C. The vertical axis shows the residual rates of vitamin D3 (upper row) and glucocorticoids (lower row) when liquid compositions (Example 6, Comparative Example 1, Comparative Example 7) were allowed to stand at 60°C. The horizontal axis shows the number of weeks elapsed since the start of standing at 60°C. 1 shows the residual rates (vertical axis) of vitamin D3 (upper row) and glucocorticoids (lower row) when liquid compositions (Example 7, Comparative Example 8, Comparative Example 9) were allowed to stand at 60°C. The horizontal axis indicates the number of weeks elapsed since the start of standing at 60°C. 1 shows the residual rates (vertical axis) of vitamin D3 (upper row) and glucocorticoids (lower row) when liquid compositions (Example 8, Comparative Example 8, Comparative Example 10) were allowed to stand at 60°C. The horizontal axis indicates the number of weeks elapsed since the start of standing at 60°C. 1 shows the residual rates (vertical axis) of vitamin D3 (upper row) and glucocorticoids (lower row) when liquid compositions (Example 9, Comparative Example 8, Comparative Example 11) were allowed to stand at 60°C. The horizontal axis indicates the number of weeks elapsed since the start of standing at 60°C. 1 shows the residual rates (vertical axis) of vitamin D3 when liquid compositions (Example 3, Example 3A) were allowed to stand at 60°C. The horizontal axis indicates the number of weeks elapsed since the start of standing at 60°C.The vertical axis shows the residual rate of vitamin D3 when the liquid compositions (Example 6 and Example 6A) were allowed to stand at 60°C. The horizontal axis shows the number of weeks elapsed since the start of standing at 60°C.

[0031] In this specification, the expressions "contain" and "comprise" include the concepts of "contain", "include", "consist essentially of" and "consist only of".

[0032] In the present specification, the number of carbon atoms in "alkylene" is, for example, 2 to 4, preferably 2 to 3, and more preferably 2.

[0033] In one aspect, the present invention relates to a composition for external use (sometimes referred to herein as the "composition for external use of the present invention") containing vitamin D3, a glucocorticoid, a nonionic surfactant A which is a polyoxyalkylene hydrogenated castor oil, and a nonionic surfactant B which is a nonionic surfactant other than polyoxyalkylene hydrogenated castor oil. This will be described below.

[0034] The vitamin D3 is not particularly limited as long as it is usable in an active vitamin D3 preparation. Examples of vitamin D3 include calcipotriol (1α,24(OH)2-22-ene-24-cyclopropyl-vitamin D3), maxacalcitol (22-oxa-1α,25-dihydroxyvitamin D3), alfacalcidol, falecalcitriol (1,25-dihydroxy-26,27-hexafluoro-vitamin D3), tacalcitol (1α,24(R)-dihydroxyvitamin D3), and calcitriol (1,25-dihydroxyvitamin D3). These components include free forms, salts, and solvates (e.g., hydrates). Among these, calcipotriol and maxacalcitol are preferred from the viewpoint of pharmaceutical stability (particularly vitamin D3). In one embodiment of the present invention, maxacalcitol is particularly preferred as the vitamin D3. In another embodiment of the present invention, the vitamin D3 is calcipotriol.

[0035] Vitamin D3 can be used alone or in combination of any two or more types.

[0036] The vitamin D3 content in the topical composition of the present invention is not particularly limited and can be, for example, 0.0001% to 0.2% by mass, preferably 0.0002% to 0.1% by mass, preferably 0.0005% to 0.05% by mass, preferably 0.001% to 0.02% by mass, and preferably 0.0015% to 0.01% by mass.

[0037] The glucocorticoid is not particularly limited as long as it can be used in steroid preparations. Examples of glucocorticoids include cortisones such as cortisone, hydrocortisone, cortisol, and corticosterone; prednisolones such as prednisolone and methylprednisolone; dexamethasone; betamethasone; and derivatives thereof. Examples of derivatives include esters such as phosphate ester, valerate ester, butyrate ester, and propionate ester, and the esters may be esters of a single acid or mixed acids. Among these, betamethasone or its esters are preferred. Among esters, betamethasone dipropionate, betamethasone butyrate ester, and propionate ester are preferred.

[0038] The glucocorticoids can be used alone or in combination of any two or more kinds.

[0039] The glucocorticoid content in the topical composition of the present invention is not particularly limited and can be, for example, 0.001% to 2% by mass, preferably 0.002% to 1% by mass, preferably 0.005% to 0.5% by mass, preferably 0.01% to 0.2% by mass, and preferably 0.015% to 0.1% by mass.

[0040] Polyoxyalkylene hydrogenated castor oil (nonionic surfactant A) is obtained by addition polymerization of alkylene oxide to hydrogenated castor oil, and is not particularly limited as long as it can be used as a nonionic surfactant. The average number of moles of alkylene oxide added is not particularly limited, but is, for example, 5 to 100. From the viewpoint of the stability of the drug (especially vitamin D3), the average number of moles added is particularly preferably 55 or less, more preferably 10 to 55, even more preferably 20 to 55, even more preferably 30 to 50, and particularly preferably 35 to 45. A particularly preferred example of the polyoxyalkylene hydrogenated castor oil is polyoxyethylene hydrogenated castor oil. Specific examples of polyoxyethylene hydrogenated castor oil include polyoxyethylene (5) hydrogenated castor oil (also called polyoxyethylene hydrogenated castor oil 5), polyoxyethylene (10) hydrogenated castor oil (also called polyoxyethylene hydrogenated castor oil 10), polyoxyethylene (20) hydrogenated castor oil (also called polyoxyethylene hydrogenated castor oil 20), polyoxyethylene (30) hydrogenated castor oil (also called polyoxyethylene hydrogenated castor oil 30), and polyoxyethylene (40) hydrogenated Examples include castor oil (also called polyoxyethylene hydrogenated castor oil 40), polyoxyethylene (50) hydrogenated castor oil (also called polyoxyethylene hydrogenated castor oil 50), polyoxyethylene (60) hydrogenated castor oil (also called polyoxyethylene hydrogenated castor oil 60), polyoxyethylene (80) hydrogenated castor oil (also called polyoxyethylene hydrogenated castor oil 80), and polyoxyethylene (100) hydrogenated castor oil (also called polyoxyethylene hydrogenated castor oil 100).

[0041] The nonionic surfactant A may be used alone or in any combination of two or more kinds.

[0042] The content of nonionic surfactant A in the topical composition of the present invention is not particularly limited, but is, for example, 0.1% by mass to 20% by mass. From the viewpoints of the stability of the drug (especially vitamin D3) and reducing stickiness of the topical composition, the content is preferably 0.2% by mass to 15% by mass, more preferably 0.5% by mass to 10% by mass, even more preferably 1% by mass to 8% by mass, still more preferably 1.5% by mass to 6% by mass, and particularly preferably 2% by mass to 5% by mass.

[0043] The nonionic surfactant B is a nonionic surfactant other than polyoxyalkylene hydrogenated castor oil, and is not particularly limited thereto. Examples of the nonionic surfactant B include polyoxyalkylene alkyl ethers, polyoxyalkylene glycols, polyoxyalkylene fatty acid esters, polyoxyalkylene sorbitan fatty acid esters, polyglycerin fatty acid esters, polyoxyalkylene glycerin fatty acid esters, and polyoxyalkylene sorbitan fatty acid esters.

[0044] Examples of polyoxyalkylene alkyl ethers include polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene stearyl ether, polyoxyethylene oleyl ether, polyoxyethylene myristyl ether, polyoxyethylene palmityl ether, polyoxyethylene isostearyl ether, polyoxyethylene hexyldecyl ether, polyoxyethylene behenyl ether, polyoxyethylene linolyl ether, polyoxyethylene capryl ether, polyoxyethylene dodecyl ether, polyoxyethylene tridecyl ether, polyoxyethylene isotridecyl ether, polyoxyethylene pentadecyl ether, polyoxyethylene cholestanol ether, polyoxyethylene octyldodecyl ether, and polyoxyethylene polyoxypropylene decyltetradecyl ether.

[0045] Examples of polyoxyalkylene glycols include polyoxyethylene polyoxypropylene glycol.

[0046] Examples of polyoxyalkylene fatty acid esters include polyethylene glycol monostearate, polyethylene glycol distearate, polyethylene glycol monooleate, polyethylene glycol dioleate, polyethylene glycol monoisostearate, and polyethylene glycol diisostearate.

[0047] Examples of polyoxyalkylene sorbite fatty acid esters include polyoxyethylene sorbite tetraoleate, polyoxyethylene sorbite hexastearate, polyoxyethylene sorbite monolaurate, and polyoxyethylene sorbite beeswax.

[0048] Examples of polyglycerin fatty acid esters include diglyceryl monocaprylate, decaglyceryl monocaprylate, hexaglyceryl monocaprate, tetraglyceryl monolaurate, hexaglyceryl monolaurate, decaglyceryl monolaurate, polyglyceryl monolaurate, decaglyceryl monomyristate, decaglyceryl monostearate, decaglyceryl monoisostearate, polyglyceryl monostearate, diglyceryl monooleate, hexaglyceryl monooleate, diglyceryl sesquioleate, polyglyceryl diisostearate, polyglyceryl distearate, diglyceryl triisostearate, and polyglyceryl tristearate.

[0049] Examples of polyoxyalkylene glycerin fatty acid esters include polyoxyethylene glycerin monostearate.

[0050] Examples of polyoxyalkylene sorbitan esters include polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan tristearate, and polyoxyethylene sorbitan trioleate.

[0051] Other examples of nonionic surfactants B besides those mentioned above include glycerin fatty acid esters, sorbitan fatty acid esters, and alkyl glyceryl ethers (ethers formed by the reaction of higher alcohols with glycerin).

[0052] From the viewpoint of more effectively improving the stability of the drug (especially vitamin D3), the HLB (Hydrophilic-Lipophilic Balance) value of the nonionic surfactant is preferably 6 or more, more preferably 6.5 or more, even more preferably 7 or more, still more preferably 7 to 19, and particularly preferably 7 to 18.

[0053] The nonionic surfactant B may be used alone or in any combination of two or more kinds.

[0054] The content of nonionic surfactant B in the topical composition of the present invention is not particularly limited, but is, for example, 0.002% by mass to 10% by mass. From the viewpoints of the stability of the drug (especially vitamin D3) and reducing stickiness of the topical composition, the content is preferably 0.005% by mass to 10% by mass, more preferably 0.01% by mass to 10% by mass, even more preferably 0.02% by mass to 10% by mass, still more preferably 0.05% by mass to 8% by mass, particularly preferably 0.1% by mass to 6% by mass, even more preferably 0.2% by mass to 4% by mass, and even more preferably 0.5% by mass to 3% by mass.

[0055] The total content of the nonionic surfactant A and the nonionic surfactant B in the topical composition of the present invention is not particularly limited, but is, for example, 0.1% by mass to 20% by mass. From the viewpoints of the stability of the drug (especially vitamin D3) and reducing stickiness of the topical composition, the content is preferably 0.5% by mass to 15% by mass, more preferably 1% by mass to 12% by mass, even more preferably 2% by mass to 10% by mass, still more preferably 3% by mass to 8% by mass, and preferably 4% by mass to 6% by mass.

[0056] The content of nonionic surfactant A in the total of nonionic surfactant A and nonionic surfactant B is not particularly limited, but is, for example, 10% by mass to 99.9% by mass. From the viewpoints of the stability of the drug (especially vitamin D3) and reducing the stickiness of the topical composition, the content is preferably 20% by mass to 99.5% by mass, more preferably 30% by mass to 99% by mass, even more preferably 40% by mass to 95% by mass, still more preferably 45% by mass to 92% by mass, and particularly preferably 45% by mass to 90% by mass.

[0057] The topical composition of the present invention preferably contains an ester oil. The ester oil can further improve the stability of the drug (especially vitamin D3). The ester oil is an oily component composed of an ester of a fatty acid and an alcohol, and is not particularly limited as long as it is liquid at room temperature (20°C).

[0058] Specific examples of the ester oil include the following:

[0059] Dibasic acid ester oils such as dioctyl succinate, diisopropyl adipate, diisobutyl adipate, dioctyl adipate, diethyl sebacate, diisopropyl sebacate, and dioctyl sebacate.

[0060] Ester oils having a hydroxyl group, such as lauryl lactate, myristyl lactate, cetyl lactate, octyldodecyl lactate, trioctyl citrate, triisocetyl citrate, trioctyldodecyl citrate, and diisostearyl malate; ester oils of straight-chain fatty acids and lower alcohols, such as isopropyl myristate, butyl myristate, isopropyl palmitate, ethyl stearate, butyl stearate, ethyl oleate, ethyl linoleate, and isopropyl linoleate; Ester oils of straight-chain fatty acids with straight-chain higher alcohols, such as cetyl caprate, hexyl laurate, decyl myristate, myristyl myristate, cetyl myristate, cetyl palmitate, stearyl stearate, decyl oleate, and oleyl oleate; ester oils of straight-chain fatty acids with branched-chain alcohols, such as perilla laurate, isotridecyl myristate, isocetyl myristate, isostearyl myristate, octyldodecyl myristate, 2-ethylhexyl palmitate, isocetyl palmitate, isostearyl palmitate, 2-ethylhexyl stearate, isocetyl stearate, isodecyl oleate, octyldodecyl oleate, and octyldodecyl ricinoleate; ester oils of branched-chain fatty acids with lower alcohols, such as ethyl isostearate and isopropyl isostearate; ester oils of branched chain fatty acids and linear higher alcohols, such as cetyl 2-ethylhexanoate, cetostearyl 2-ethylhexanoate, stearyl 2-ethylhexanoate, hexyl isostearate, and 2-hexyldecyl isostearate;Ester oils of fatty acids and polyhydric alcohols such as ethylene glycol dioctanoate, ethylene glycol dioleate, propylene glycol dicaprylate, propylene glycol di(caprylic / capric acid), propylene glycol dicaprate, dipropylene glycol dioleate, neopentyl glycol dicaprate, neopentyl glycol dioctanoate, glyceryl tricaprylate, glyceryl tri-2-ethylhexanoate, glycerin triisooctanoate, glyceryl tri(caprylic / capric acid), glyceryl triisopalmitate, glyceryl triisostearate, trimethylolpropane triisostearate, pentaerythritol tetra-2-ethylhexanoate, pentaerythritol tetraisostearate, and pentaerythritol tetra-2-ethylhexanoate; Ester oils of branched chain fatty acids and branched chain alcohols, such as octyldodecyl neopentanoate, isocetyl octanoate, isostearyl octanoate, 2-ethylhexyl isopelargonate, hexyldecyl dimethyloctanoate, octyldodecyl dimethyloctanoate, 2-ethylhexyl isopalmitate, isocetyl isostearate, isostearyl isostearate, and octyldodecyl isostearate;

[0061] Among the above specific examples, the topical composition of the present invention can preferably contain an ester oil of a dibasic acid from the viewpoint of the stability of the drug (particularly vitamin D3), etc. From the same viewpoint, the ester oil of a dibasic acid can more preferably contain a diester (preferably a symmetric diester) of a dicarboxylic acid (preferably a linear dicarboxylic acid) having 4 to 8 (preferably 5 to 7) carbon atoms in its main chain and an alkyl alcohol (preferably an alkyl alcohol having 2 to 10, preferably 3 to 10, more preferably 3 to 6 carbon atoms).

[0062] In one embodiment of the present invention, the ester oil may contain at least glycerin triisooctanoate.

[0063] The ester oils may be used singly or in any combination of two or more.

[0064] When the topical composition of the present invention contains an ester oil, the content of the ester oil in the topical composition of the present invention is not particularly limited and is, for example, more than 0% by mass and not more than 10% by mass. From the viewpoint of the stability of the drug (especially vitamin D3), the content is preferably 0.005% by mass to 10% by mass, more preferably 0.05% by mass to 10% by mass, even more preferably 0.1% by mass to 8% by mass, still more preferably 0.2% by mass to 6% by mass, particularly preferably 0.5% by mass to 4% by mass, and especially preferably 1% by mass to 2% by mass.

[0065] The topical composition of the present invention usually contains water. The water content in the composition of the present invention is, for example, 40% by weight or more, preferably 50% by weight or more, more preferably 60% by weight or more, even more preferably 70% by weight or more, even more preferably 75% by weight or more, particularly preferably 80% by weight or more, particularly preferably 85% by weight or more, and particularly preferably 90% by weight or more. The upper limit of the content can be, for example, 95% by weight, 90% by weight, 85% by weight, or 80% by weight. The above lower and upper limits can be arbitrarily combined. The topical composition of the present invention can effectively improve the stability of vitamin D3 even when the water content is higher and the stability problem of vitamin D3 becomes more serious.

[0066] When the topical composition of the present invention contains water, the pH of the topical composition of the present invention is preferably 6 to 8, more preferably 6.5 to 7.5, even more preferably 6.7 to 7.3, even more preferably 6.8 to 7.2, and particularly preferably 6.9 to 7.1, from the viewpoint of the stability of the drug (especially vitamin D3).

[0067] In one embodiment of the present invention, the topical composition of the present invention may contain other ingredients in addition to those described above. Examples of other ingredients include hydrocarbons (e.g., liquid paraffin (e.g., light liquid paraffin), squalane, etc.), solvents (e.g., benzyl alcohol, methyl ethyl ketone, N-alkylpyrrolidone, alkylene carbonate, acetone, ethanol, isopropanol, propylene glycol, 1,3-butylene glycol, concentrated glycerin, polyethylene glycol, hexylene glycol, propylene carbonate, etc.), water-soluble polymers (e.g., carboxyvinyl polymer, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, chitosan, povidone, polyvinyl alcohol, gelatin, casein, carrageenan, sodium hyaluronate, 2-methacryloyloxyethylphosphorylcholine-butyl methacrylate copolymer, xanthan gum, polyethylene glycol, etc.), antioxidants, pH adjusters, preservatives, stabilizers, amino acids, chelating agents, and amphoteric surfactants such as hydrogenated lecithin. These may be used alone or in any combination of two or more. The topical composition of the present invention may also contain other active ingredients other than the vitamin D3 and glucocorticoids, such as moisturizers, anti-inflammatory agents, vitamins, antibacterial agents, disinfectants, antiviral agents, steroids, antibiotics, antipruritic agents, antiimmunosuppressants, local anesthetics, and whitening agents.

[0068] In one embodiment of the present invention, the topical composition of the present invention contains hydrocarbons (hydrocarbon oils).

[0069] In one embodiment of the present invention, the topical composition of the present invention contains an antioxidant.

[0070] Examples of antioxidants include fat-soluble antioxidants, water-soluble antioxidants, etc. Examples of fat-soluble antioxidants include butyl-containing phenols such as dibutylhydroxytoluene (BHT) and butylhydroxyanisole (BHA); nordihydroguaiaretic acid (NDGA); ascorbic acid esters such as ascorbic acid palmitate, ascorbic acid stearate, ascorbic acid aminopropyl phosphate, ascorbic acid tocopherol phosphate, dl-α-tocopherol, d-δ-tocopherol, tocopherol acetate, ascorbic acid triphosphate, and ascorbic acid palmitate; gallic acid esters such as ethyl gallate, propyl gallate, octyl gallate, and dodecyl gallate; propyl gallate; 3-butyl-4-hydroxyquinolin-2-one; carotenoids such as lutein and astaxanthin; polyphenols such as anthocyanins, catechins, tannins, and curcumin; CoQ10, etc. Examples of water-soluble antioxidants include ascorbic acid, ascorbic acid derivatives (disodium ascorbyl 2-sulfate, sodium ascorbate, magnesium ascorbyl 2-phosphate, sodium ascorbyl 2-phosphate, etc.), sodium hydrogensulfite, sodium sulfite, sodium pyrosulfite, sodium thiosulfate, edetic acid or its salts (sodium edetate, disodium edetate, tetrasodium edetate), etc. Preferred antioxidants include fat-soluble antioxidants, and among these, butyl group-containing phenols are more preferred, with dibutylhydroxytoluene being particularly preferred.

[0071] When the topical composition of the present invention contains an antioxidant, the content of the antioxidant in the topical composition of the present invention is, for example, 0.001 to 5% by mass, preferably 0.01 to 2% by mass, and more preferably 0.05 to 0.5% by mass.

[0072] The content of other ingredients in the topical composition of the present invention is not particularly limited as long as it does not significantly impair the effects of the present invention, and may be, for example, from 0% to 10% by mass, from 0% to 5% by mass, from 0% to 2% by mass, from 0% to 1% by mass, or from 0% to 0.1% by mass.

[0073] The topical composition of the present invention can be used for application to the skin. The topical composition of the present invention can be one for application to the skin (excluding those for application to hair (e.g., shampoos and rinses)). The topical composition of the present invention is preferably in the form of a topical composition for the skin, such as a topical skin medicine or cosmetic. The topical composition of the present invention is used in a manner that does not require removal after application, and is distinct from cleansing agents that are intended to be removed with water (e.g., rinsed off) after lathering.

[0074] The topical composition of the present invention is not particularly limited in its form, and may take any known form as a cosmetic or quasi-drug. Examples of such known forms include solutions, suspensions, emulsions, creams, gels, liniments, lotions, aerosols, powders, poultices, sheets such as nonwoven fabrics impregnated with a medicinal solution, and lip emulsions. Among these, solutions, suspensions, emulsions, creams, gels, and lotions are preferred because of their pleasant feel when used, and transparent solutions are particularly preferred.

[0075] In one embodiment of the present invention, the topical composition of the present invention is in the form of a gel, liquid, aerosol, mist, or foam.

[0076] The topical composition of the present invention can be prepared by mixing each component with a solvent. The composition of the present invention is preferably in a solubilized state. A solubilized state refers to a state in which the surfactant forms micelles, dissolves uniformly, and forms a transparent, single-phase solution. The solubilized state also includes a microemulsion state. A microemulsion is a thermodynamically stable micellar solution consisting of emulsion particles with a particle size of 100 nm or less. The solubilized state can be confirmed by its transparent appearance. Alternatively, the solubilized state can be confirmed by measuring particle size using conventional methods. A solubilized composition can be obtained by dissolving each component under heating, as needed, followed by cooling.

[0077] The topical composition of the present invention is preferably a composition filled into a non-gas type foam-dispensing device. Here, a non-gas type foam-dispensing device refers to a device equipped with a foaming mechanism without relying on a propellant. In other words, the topical composition of the present invention is preferably one that is foamed using a non-gas type foam-dispensing device. Examples of non-gas type foam-dispensing devices include screen-type foam-dispensing devices. Screen-type foam-dispensing devices refer to devices that pressurize a liquid and pass it through a net-like screen (mesh), thereby mixing it with air and foaming it. Examples of screen-type foam-dispensing devices include pump-type foam-dispensing devices, tube-type foam-dispensing devices, and squeeze-type foam-dispensing devices. Among these, pump-type foam-dispensing devices are preferred.

[0078] As the non-gas type foam discharge device, known devices, commercially available devices, etc. can be used. For example, in the case of a pump type foam discharge device, those described in JP 2012-45525 A, JP 2008-307478 A, etc. can be used.

[0079] The topical composition of the present invention can be used, for example, to prevent or improve psoriasis.

[0080] "Amelioration" includes not only attenuation or elimination of symptoms, but also suppression of the degree of worsening of symptoms or cessation of worsening of symptoms when the symptoms continue to worsen.

[0081] Psoriasis is not particularly limited, and examples include psoriasis vulgaris, psoriatic arthritis, guttate psoriasis, erythrodermic psoriasis, and pustular psoriasis.

[0082] The topical composition of the present invention can be applied to mammals, including humans, for example, daily or once every few days, preferably continuously for a period of at least 2 weeks, more preferably at least 3 weeks, and even more preferably at least 4 weeks.

[0083] The present invention will be described in detail below based on examples, but the present invention is not limited to these examples.

[0084] Materials Details of the materials used in the following test examples are as follows: POE means polyoxyethylene, and POP means polyoxypropylene.

[0085] (a1. Active ingredient: Vitamin D3) - Calcipotriol monohydrate - Maxacalcitol.

[0086] (a2. Active pharmaceutical ingredients: glucocorticoids) - Betamethasone dipropionate - Betamethasone butyrate propionate.

[0087] (b. Nonionic surfactant A) Polyoxyethylene hydrogenated castor oil 40 (HLB value 12.5). "40" indicates the average number of moles of ethylene oxide added.

[0088] (c1. Nonionic surfactant B: Polyoxyalkylene alkyl ether) - POE(20)POP(4) cetyl ether (HLB value 12.5) - POE lauryl ether (HLB value 14.5).

[0089] (c2. Nonionic surfactant B: Polyoxyalkylene glycol) - POEPOP glycol (HLB value 10.9).

[0090] (c3. Nonionic surfactant B: Polyoxyalkylene fatty acid ester) - Polyethylene glycol monostearate (HLB value 17.5).

[0091] (c4. Nonionic surfactant B: Polyoxyalkylene sorbite fatty acid ester) and polyoxyethylene sorbite tetraoleate (HLB value 15.5).

[0092] (c5. Nonionic surfactant B: Polyglycerin fatty acid ester) - Polyglyceryl monolaurate (HLB value 15.5).

[0093] (d. Ester oil) • Diisopropyl adipate • Glyceryl triisooctanoate.

[0094] (e. pH adjusters) - Sodium hydroxide - Sodium citrate hydrate - Citric acid hydrate.

[0095] Test Example 1. Evaluation Test 1 for Drug Substance Stability Liquid compositions (Examples 1 to 9, Comparative Examples 1 to 11) were prepared according to the formulations shown in Tables 1 and 2 (numbers are in mass %, and blanks indicate 0). Specifically, the above-mentioned group a (a1 and a2) and group d were dissolved, and then group b and group c (c1, c2, c3, c4, or c5) were added and dissolved again. Water was then added and the mixture was stirred and dissolved to obtain a liquid composition. The pH of the liquid composition was adjusted to pH 7.0 by adding a pH adjuster (appropriate amount in the tables: 0.002 to 0.01 mass %) as shown in Tables 1 and 2.

[0096] The stability of vitamin D3 and glucocorticoid in the resulting liquid composition was measured. Specifically, the liquid composition was left to stand at 60°C, and the vitamin D3 and glucocorticoid contents were analyzed by HPLC after 1 week, 2 weeks, and 3 weeks. The peak areas of the samples were measured by automatic integration, and the remaining percentages of vitamin D3 and glucocorticoid were calculated.

[0097]

[0098]

[0099] The results are shown in Figures 1 to 9. It was found that a synergistic effect was achieved in improving the stability of vitamin D3 by combining nonionic surfactant A, which is polyoxyalkylene hydrogenated castor oil, with nonionic surfactant B, which is a nonionic surfactant other than polyoxyalkylene hydrogenated castor oil. It was also found that this combination did not adversely affect the stability of glucocorticoids.

[0100] Test Example 2. Evaluation Test 2 of Drug Substance Stability Liquid compositions were prepared in the same manner as in Examples 3 and 6 of the present application, except that an antioxidant (dibutylhydroxytoluene) was added to a concentration of 0.1% by mass (Examples 3A and 6A). The stability of vitamin D3 in the obtained liquid compositions was measured according to the method described in Test Example 1.

[0101] The results are shown in Figures 10 and 11. It was found that antioxidants do not adversely affect the stability of vitamin D3, but rather improve the stability of vitamin D3.

Claims

1. A composition for external use comprising vitamin D3, a glucocorticoid, nonionic surfactant A which is polyoxyalkylene hydrogenated castor oil, and nonionic surfactant B which is a nonionic surfactant other than polyoxyalkylene hydrogenated castor oil.

2. The topical composition according to claim 1, wherein the nonionic surfactant B is at least one selected from the group consisting of polyoxyalkylene alkyl ethers, polyoxyalkylene glycols, polyoxyalkylene fatty acid esters, polyoxyalkylene sorbite fatty acid esters, and polyglycerin fatty acid esters.

3. The topical composition according to claim 1, wherein the HLB value of the nonionic surfactant B is 6 or higher.

4. The topical composition according to claim 1, wherein the total content of the nonionic surfactant A and the nonionic surfactant B in the topical composition is 0.5% by mass or more and 10% by mass or less.

5. The topical composition according to claim 1, wherein the content of said nonionic surfactant A in the total of said nonionic surfactant A and said nonionic surfactant B is 10% by mass or more and 99.9% by mass or less.

6. The topical composition according to claim 1, which contains an ester oil.

7. The topical composition according to claim 6, wherein the ester oil comprises at least glycerin triisooctanoate.

8. The topical composition according to claim 1, wherein the nonionic surfactant B is at least one selected from the group consisting of polyoxyalkylene alkyl ethers, polyoxyalkylene glycols, polyoxyalkylene fatty acid esters, polyoxyalkylene sorbite fatty acid esters, and polyglycerin fatty acid esters; the HLB value of the nonionic surfactant B is 6 or higher; the total content of the nonionic surfactant A and the nonionic surfactant B in the topical composition is 1% by mass or more and 10% by mass or less; the content of the nonionic surfactant A in the total of the nonionic surfactant A and the nonionic surfactant B is 10% by mass or more and 99.9% by mass or less; and the topical composition contains ester oil.

9. The topical composition according to claim 1, wherein the vitamin D3 is at least one selected from the group consisting of calcipotriol, maxacalcitol, alphacalcidol, falecalcitriol, tacalcitol, and calcitriol.

10. The topical composition according to claim 1, wherein the vitamin D3 is calcipotriol, the glucocorticoid is betamethasone dipropionate, the polyoxyalkylene hydrogenated castor oil is polyoxyethylene hydrogenated castor oil, and the nonionic surfactant B is at least one selected from the group consisting of polyoxyalkylene alkyl ethers, polyoxyalkylene glycols, polyoxyalkylene fatty acid esters, polyoxyalkylene sorbite fatty acid esters, and polyglycerin fatty acid esters.

11. The topical composition according to claim 1, 2, 8, or 10, wherein the nonionic surfactant B is one or more selected from polyoxyethylene polyoxypropylene cetyl ether, polyoxyethylene lauryl ether, polyoxyethylene polyoxypropylene glycol, polyethylene glycol monostearate, polyoxyethylene sorbitol tetraoleate, and polyglyceryl monolaurate.

12. The topical composition according to claim 1, wherein the average number of moles of alkylene oxide added in the polyoxyalkylene hydrogenated castor oil is less than 60.

13. The topical composition according to claim 12, wherein the alkylene oxide group is ethylene oxide.

14. The topical composition according to claim 10, wherein the average number of moles of ethylene oxide added to the polyoxyethylene hydrogenated castor oil is less than 60.

15. The composition for external use according to any one of claims 1 to 10 and 12 to 14, further comprising water.

16. The topical composition according to claim 15, wherein the water content in the topical composition is 40% by mass or more.

17. The topical composition according to claim 15, wherein the water content in the topical composition is 75% by mass or more.

18. A composition for external use described in any one of claims 1 to 10 and 12 to 14, wherein the content of vitamin D3 in the composition for external use is 0.0001% by mass or more and 0.2% by mass or less.

19. A composition for external use according to any one of claims 1 to 10 and 12 to 14, wherein the content of the glucocorticoid in the composition for external use is 0.001% by mass or more and 2% by mass or less.

20. The topical composition according to any one of claims 1 to 10 and 12 to 14, further comprising an antioxidant.

21. The composition for external use according to any one of claims 1 to 10 and 12 to 14, which is in the form of a gel, liquid, aerosol, mist, or foam.

22. A composition for external use according to any one of claims 1 to 10 and 12 to 14, which is used for the prevention or amelioration of psoriasis.

Citation Information

Patent Citations

  • Foam discharger

    JP2008307478A

  • Pump foamer and pump foamer case

    JP2012045525A

  • Topical Compositions

    JP2021518409A

  • Skin care medicine preparation for external use

    JP2005200328A

  • Skin care composition

    JP2006265135A